Sanofi-Aventis Czech Republic

Profit Statement 2015 2016 2017
Sales CZK mil 6,596 6,700 7,268
Gross Profit CZK mil 693 538 1,684
EBITDA CZK mil 94.6 20.1 50.7
EBIT CZK mil 89.5 15.5 39.0
Financing Cost CZK mil 2.24 2.75 5.09
Pre-Tax Profit CZK mil 87.2 12.7 33.9
Net Profit CZK mil 58.6 37.0 15.2
Balance Sheet 2015 2016 2017
Total Assets CZK mil 2,635 2,864 3,210
Non-Current Assets CZK mil 34.3 31.6 132
Current Assets CZK mil 2,597 2,829 3,075
Working Capital CZK mil 1,420 1,626 1,745
Shareholders' Equity CZK mil 699 738 752
Liabilities CZK mil 1,937 2,126 2,458
Total Debt CZK mil 404 586 775
Net Debt CZK mil 404 574 774
Ratios 2015 2016 2017
ROE % 8.76 5.15 2.05
ROCE % 4.39 2.38 0.863
Gross Margin % 10.5 8.03 23.2
EBITDA Margin % 1.43 0.301 0.698
EBIT Margin % 1.36 0.231 0.536
Net Margin % 0.889 0.553 0.210
Net Debt/EBITDA 4.27 28.5 15.3
Net Debt/Equity % 57.8 77.8 103
Cost of Financing % 0.511 0.556 0.748
Cash Flow 2015 2016 2017
Total Cash From Operations CZK mil 70.6 -159 -90.1
Total Cash From Investing CZK mil -2.71 -1.99 -110
Total Cash From Financing CZK mil -67.1 182 189
Net Change In Cash CZK mil 0.726 20.9 -11.1
Cash Conversion Cycle days 79.3 89.6 89.5
Cash Earnings CZK mil 63.7 41.7 27.0
Free Cash Flow CZK mil 67.8 -161 -200

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                            
Sales CZK mil               7,040 7,225 6,531 6,120 6,596    
Gross Profit CZK mil               536 574 605 485 693    
EBIT CZK mil               82.9 71.4 89.3 9.99 89.5    
Net Profit CZK mil               55.1 45.2 65.2 1.19 58.6    
ROE %               11.0 8.21 10.8 0.186 8.76    
EBIT Margin %               1.18 0.988 1.37 0.163 1.36    
Net Margin %               0.782 0.626 0.998 0.019 0.889    
Employees               297 377 371 373 415    
balance sheet                            
Total Assets CZK mil               3,167 3,297 2,694 2,348 2,635    
Non-Current Assets CZK mil               46.9 51.1 45.0 36.7 34.3    
Current Assets CZK mil               3,102 3,237 2,644 2,307 2,597    
Shareholders' Equity CZK mil               528 574 639 640 699    
Liabilities CZK mil               2,639 2,724 2,055 1,708 1,937    
Non-Current Liabilities CZK mil               169 121 0 0 0    
Current Liabilities CZK mil               2,470 2,603 1,887 1,602 1,838    
Net Debt/EBITDA               12.8 16.5 8.87 27.7 4.27    
Net Debt/Equity %               221 232 137 73.7 57.8    
Cost of Financing % ...             1.59 1.50 0.956 1.24 0.511    
cash flow                            
Total Cash From Operations CZK mil               58.5 -155 460 404 70.6    
Total Cash From Investing CZK mil               -9.97 -13.5 -3.03 1.31 -2.71    
Total Cash From Financing CZK mil               -99.4 245 0 0 -67.1    
Net Change In Cash CZK mil               -50.8 77.1 457 405 0.726    
income statement Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
income statement                            
Sales CZK mil               7,040 7,225 6,531 6,120 6,596    
Cost of Goods & Services CZK mil               6,505 6,651 5,927 5,635 5,903    
Gross Profit CZK mil               536 574 605 485 693    
Staff Cost CZK mil               334 427 433 427 509    
Other Cost CZK mil               111 66.7 72.1 41.6 89.5    
EBITDA CZK mil               90.8 80.9 98.9 17.0 94.6    
Depreciation CZK mil               7.90 9.55 9.60 7.04 5.12    
EBIT CZK mil               82.9 71.4 89.3 9.99 89.5    
Financing Cost CZK mil               19.3 19.3 11.0 8.40 2.24    
Extraordinary Cost CZK mil               0 0 0 0 0    
Pre-Tax Profit CZK mil               63.6 52.0 78.4 1.59 87.2    
Tax CZK mil               8.55 6.81 13.2 0.401 28.6    
Minorities CZK mil               0 0 0 0 0    
Net Profit CZK mil               55.1 45.2 65.2 1.19 58.6    
growth rates                            
Total Revenue Growth % ...             -6.44 2.62 -9.60 -6.30 7.77    
Operating Cost Growth % ...             2.80 10.9 2.48 -7.42 27.8    
EBITDA Growth % ...             26.7 -10.9 22.2 -82.8 455    
EBIT Growth % ...             29.9 -13.9 25.2 -88.8 796    
Pre-Tax Profit Growth % ...             51.8 -18.2 50.6 -98.0 5,393    
Net Profit Growth % ...             18.2 -17.9 44.2 -98.2 4,839    
ratios                            
ROE %               11.0 8.21 10.8 0.186 8.76    
ROCE % ...             2.97 2.37 3.65 0.083 4.39    
Gross Margin %               7.61 7.95 9.26 7.93 10.5    
EBITDA Margin %               1.29 1.12 1.51 0.278 1.43    
EBIT Margin %               1.18 0.988 1.37 0.163 1.36    
Net Margin %               0.782 0.626 0.998 0.019 0.889    
Cost of Financing % ...             1.59 1.50 0.956 1.24 0.511    
Net Debt/EBITDA               12.8 16.5 8.87 27.7 4.27    
balance sheet Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
balance sheet                            
Non-Current Assets CZK mil               46.9 51.1 45.0 36.7 34.3    
Property, Plant & Equipment CZK mil               39.6 45.3 40.4 35.4 34.0    
Intangible Assets CZK mil               5.90 4.39 3.12 1.30 0.328    
Current Assets CZK mil               3,102 3,237 2,644 2,307 2,597    
Inventories CZK mil               1,347 1,415 1,182 1,028 1,294    
Receivables CZK mil               1,573 1,506 1,293 1,112 1,302    
Cash & Cash Equivalents CZK mil               0.106 77.2 5.67 0.065 0.791    
Total Assets CZK mil               3,167 3,297 2,694 2,348 2,635    
Shareholders' Equity CZK mil               528 574 639 640 699    
Of Which Minority Interest CZK mil               0 0 0 0 0    
Liabilities CZK mil               2,639 2,724 2,055 1,708 1,937    
Non-Current Liabilities CZK mil               169 121 0 0 0    
Long-Term Debt CZK mil               0 0 0 0 0    
Deferred Tax Liabilities CZK mil               0 0 0 0 0    
Current Liabilities CZK mil               2,470 2,603 1,887 1,602 1,838    
Short-Term Debt CZK mil               1,165 1,410 883 471 404    
Trade Payables CZK mil               1,094 1,033 887 963 1,176    
Provisions CZK mil               68.7 67.5 53.8 52.6 99.1    
Equity And Liabilities CZK mil               3,167 3,297 2,694 2,348 2,635    
growth rates                            
Total Asset Growth % ...             1.84 4.11 -18.3 -12.8 12.2    
Shareholders' Equity Growth % ...             11.6 8.56 11.4 0.186 9.16    
Net Debt Growth % ...             -4.00 14.4 -34.2 -46.3 -14.4    
Total Debt Growth % ...             -7.86 21.0 -37.4 -46.6 -14.2    
ratios                            
Total Debt CZK mil               1,165 1,410 883 471 404    
Net Debt CZK mil               1,165 1,333 877 471 404    
Working Capital CZK mil               1,826 1,888 1,588 1,177 1,420    
Capital Employed CZK mil               1,873 1,939 1,633 1,214 1,454    
Net Debt/Equity %               221 232 137 73.7 57.8    
Cost of Financing % ...             1.59 1.50 0.956 1.24 0.511    
cash flow Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
cash flow                            
Net Profit CZK mil               55.1 45.2 65.2 1.19 58.6    
Depreciation CZK mil               7.90 9.55 9.60 7.04 5.12    
Non-Cash Items CZK mil ...             31.3 -148 86.0 -15.6 249    
Change in Working Capital CZK mil ...             -35.8 -61.9 299 411 -243    
Total Cash From Operations CZK mil               58.5 -155 460 404 70.6    
Capital Expenditures CZK mil               -10.1 -13.6 -3.17 1.20 -2.77    
Other Investments CZK mil               0.139 0.061 0.137 0.113 0.061    
Total Cash From Investing CZK mil               -9.97 -13.5 -3.03 1.31 -2.71    
Issuance Of Debt CZK mil ...             -99.4 245 -527 -412 -67.1    
Total Cash From Financing CZK mil               -99.4 245 0 0 -67.1    
Net Change In Cash CZK mil               -50.8 77.1 457 405 0.726    
ratios                            
Days Sales Outstanding days               81.5 76.1 72.3 66.3 72.1    
Days Sales Of Inventory days               75.6 77.6 72.8 66.6 80.0    
Days Payable Outstanding days               61.4 56.7 54.6 62.4 72.7    
Cash Conversion Cycle days               95.7 97.0 90.4 70.6 79.3    
Cash Earnings CZK mil               63.0 54.8 74.8 8.23 63.7    
Free Cash Flow CZK mil               48.5 -168 457 405 67.8    
other data Unit 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
other data                            
ROA %               1.75 1.40 2.18 0.047 2.35    
Gross Margin %               7.61 7.95 9.26 7.93 10.5    
Employees               297 377 371 373 415    
Cost Per Employee USD per month               5,298 4,822 4,976 4,458 4,280    
Cost Per Employee (Local Currency) CZK per month               93,703 94,321 97,365 95,287 102,155    
Staff Cost (As % Of Total Cost) %               4.80 5.96 6.73 6.98 7.82    
Effective Tax Rate %               13.4 13.1 16.8 25.3 32.8    
Domestic Sales CZK mil ... ... ... ...       5,834 6,015 5,532 5,229 5,488    
Capital Expenditures (As % of Sales) %               0.144 0.188 0.049 -0.020 0.042    
Revenues From Abroad CZK mil ... ... ... ...       1,206 1,210 1,000 891 1,108    
Revenues From Abroad (As % Of Total) % ... ... ... ...       17.1 16.7 15.3 14.6 16.8    

Get all company financials in excel:

Download Sample   $19.99

Sanofi-Aventis s.r.o. is a Czech Republic-based subsidiary of the multinational pharmaceutical company Sanofi S.A. The Czech Company is the owner of Zentiva, the Prague-based branded generics producer, which was bought by Sanofi in 2008 for EUR 1.8 bil. Sanofi S.A. is the world's fifth-largest pharmaceutical company by prescription sales. The Company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines.

Sanofi-Aventis Czech Republic Logo